The efficacy of botulinum toxin type A in managing chronic musculoskeletal pain: a systematic review and meta analysis

@article{Zhang2010TheEO,
  title={The efficacy of botulinum toxin type A in managing chronic musculoskeletal pain: a systematic review and meta analysis},
  author={Tony Zhang and Aleem Adatia and Wasifa Zarin and Misha O Moitri and Abi Vijenthira and Rong Chu and Lehana Thabane and Walter F. Kean},
  journal={Inflammopharmacology},
  year={2010},
  volume={19},
  pages={21-34}
}
Botulinum toxin type A (BoNTA) is a neurotoxin that acts by inhibiting the release of neurotransmitters acetylcholine at neuromuscular junctions, thus reducing muscular contractions. Recent evidence suggests that BoNTA can reduce nociceptive activities of sensory neurons in animal models by inhibiting release of certain neuropeptides. Despite the therapeutic benefit of BoNTA in alleviating painful muscle spasms, its efficacy in other musculoskeletal pain conditions is less clear. We aim to… CONTINUE READING

7 Figures & Tables

Connections & Topics

Mentioned Connections BETA
Botulinum toxin type A ( BoNTA ) is a neurotoxin that acts by inhibiting the release of neurotransmitters acetylcholine at neuromuscular junctions , thus reducing muscular contractions .
Botulinum toxin type A ( BoNTA ) is a neurotoxin that acts by inhibiting the release of neurotransmitters acetylcholine at neuromuscular junctions , thus reducing muscular contractions .
All Topics